| First Author | Kim U | Year | 2024 |
| Journal | iScience | Volume | 27 |
| Issue | 4 | Pages | 109366 |
| PubMed ID | 38510127 | Mgi Jnum | J:346388 |
| Mgi Id | MGI:7615771 | Doi | 10.1016/j.isci.2024.109366 |
| Citation | Kim U, et al. (2024) DeltaNp63 regulates MDSC survival and metabolism in triple-negative breast cancer. iScience 27(4):109366 |
| abstractText | Triple-negative breast cancer (TNBC) contributes greatly to mortality of breast cancer, demanding new targetable options. We have shown that TNBC patients have high DeltaNp63 expression in tumors. However, the function of DeltaNp63 in established TNBC is yet to be explored. In current studies, targeting DeltaNp63 with inducible CRISPR knockout and Histone deacetylase inhibitor Quisinostat showed that DeltaNp63 is important for tumor progression and metastasis in established tumors by promoting myeloid-derived suppressor cell (MDSC) survival through tumor necrosis factor alpha. Decreasing DeltaNp63 levels are associated with decreased CD4(+) and FOXP3(+) T-cells but increased CD8(+) T-cells. RNA sequencing analysis indicates that loss of DeltaNp63 alters multiple MDSC properties such as lipid metabolism, chemotaxis, migration, and neutrophil degranulation besides survival. We further demonstrated that targeting DeltaNp63 sensitizes chemotherapy. Overall, we showed that DeltaNp63 reprograms the MDSC-mediated immunosuppressive functions in TNBC, highlighting the benefit of targeting DeltaNp63 in chemotherapy-resistant TNBC. |
